Product Images Tukysa

This is a prescription drug named TUKYSA (tucatinib) used for medical purposes. Each container contains 60 tablets of 150 mg tucatinib. The recommended dosage should be taken as per the prescribing information. The tablets should be stored at controlled room temperature and should be kept away from children. The unused tablets should be discarded 3 months after opening. This drug is manufactured and trademarked by Seagen Inc. The package has a unique identification number and an expiration date.*

TUKYSA is a drug available in the form of tablets. Each tablet contains tucatinib. The recommended dosage and other important information is available in the prescribing information. The tablets should be stored at a controlled room temperature and should be discarded if unused after three months of opening. TUKYSA is a registered trademark of Sesgen Inc., a subsidiary of Seagen Inc. There is no other useful information for a reader in this text.*

Tukysa is a medication that comes in tablet form and is only available with a prescription, containing 50mg of fucatifib per tablet. The recommended dosage should be obtained from the prescribing information. The tablets should be stored in a cool, dry place between 20°C and 25°C (68°F to 77°F); brief excursions are permitted from 15°C to 30°C (59°F to 86°F). Tukysa should be kept in the original container out of the reach of children, with unused tablets discarded three months after the opening. This medicine is a registered trademark of Seagen Inc.*

The text describes a Kaplan-Meier curve graph showing the progression-free survival (PFS) per BICR (Blinded Independent Central Review) in HER2CLIMB, a clinical trial evaluating the efficacy of Tukysa, Tras, and Cape over Pbo, Tras, and Cape in patients with HER2-positive metastatic breast cancer. The x-axis represents the months since randomization, while the y-axis represents the PFS percentage. The text also includes data on the number of patients "at risk" per treatment group at each time point.*

This is a Kaplan-Meier curve which represents the overall survival of patients in the HER2CLIMB clinical trial. The X-axis represents the months since randomization and the Y-axis represents the proportions of patients still alive. The blue line represents the group of patients who received Tukysa+Tras+Cape treatment while the orange line represents the group of patients who received Pbo+Tras+Cape treatment. At each time point, the number of patients at risk is displayed below the graph.*